Cyclin Y inhibitors belong to a class of chemical compounds designed to specifically target and modulate the activity of cyclin Y, a regulatory protein involved in cell cycle progression. Cyclin Y is a relatively newly discovered member of the cyclin family of proteins, which play critical roles in controlling cell division and proliferation. The inhibition of cyclin Y is primarily studied for its potential impact on cellular processes and its association with certain pathological conditions. These inhibitors are designed to interfere with the function of cyclin Y, thereby influencing the cell cycle and potentially offering insights into the fundamental mechanisms underlying cell division and growth regulation.
Cyclin Y inhibitors are typically small molecules that interact with specific binding sites on cyclin Y or its associated proteins. These interactions can disrupt the formation of active cyclin Y-CDK (Cyclin-Dependent Kinase) complexes, thereby preventing the activation of downstream signaling pathways involved in cell cycle control. By modulating cyclin Y activity, these inhibitors offer a valuable tool for researchers to dissect the intricate regulatory networks governing cell division. Moreover, understanding the molecular mechanisms through which cyclin Y inhibitors operate can shed light on the broader dynamics of cell cycle progression, making them a vital component of basic research aimed at elucidating the complexities of cellular biology and potentially identifying new avenues for further investigation into the role of cyclin Y in health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
RO-3306 | 872573-93-8 | sc-358700 sc-358700A sc-358700B | 1 mg 5 mg 25 mg | $65.00 $160.00 $320.00 | 37 | |
Ro-3306 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1) which regulates the G2/M cell cycle transition by inhibiting CDK1 activity, preventing cell cycle progression. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is a CDK inhibitor that targets CDK1, CDK2, and CDK9, blocking cell cycle progression and transcription in cancer cells. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib inhibits CDK1, CDK2, CDK5, and CDK9, disrupting cell cycle progression and inhibiting transcription in cancer cells. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is a broad-spectrum CDK inhibitor that targets multiple CDKs, leading to cell cycle arrest and apoptosis in cancer cells. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 inhibits CDK2, CDK7, and CDK9, preventing cell cycle progression and transcription in cancer cells. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib specifically inhibits CDK4 and CDK6, halting cell cycle progression in hormone receptor-positive breast cancer. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547 inhibits CDK1, CDK2, and CDK4, disrupting cell cycle regulation and inducing apoptosis in cancer cells. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
LY2835219 is a CDK4 and CDK6 inhibitor used to halt cell cycle progression in hormone receptor-positive breast cancer. | ||||||
Zotiraciclib | 937270-47-8 | sc-507450 | 10 mg | $202.00 | ||
This compound, also called TG-02, inhibits CDK2, CDK7, and CDK9, affecting cell cycle progression and transcription in cancer cells. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib is a CDK4 and CDK6 inhibitor used to block cell cycle progression in hormone receptor-positive breast cancer. | ||||||